CoChat
Sign Up
Cited by 1,352Smoking Behavior and CessationSubstance Abuse Treatment and OutcomesNicotinic Acetylcholine Receptors Study

Antidepressants for smoking cessation

Open access
Howes, Seth, Hartmann-Boyce, Jamie, Livingstone-Banks, Jonathan, Hong, Bosun, Lindson, Nicola·2020·Cochrane Database of Systematic Reviews
DOI 10.1002/14651858.cd000031.pub5PMC PMC7175455
Open this paper in CoChat — free account

Abstract

BACKGROUND: Whilst the pharmacological profiles and mechanisms of antidepressants are varied, there are common reasons why they might help people to stop smoking tobacco. Firstly, nicotine withdrawal may produce depressive symptoms and antidepressants may relieve these. Additionally, some antidepressants may have a specific effect on neural pathways or receptors that underlie nicotine addiction. OBJECTIVES: To assess the evidence for the efficacy, safety and tolerability of medications with antidepressant properties in assisting long-term tobacco smoking cessation in people who smoke cigarettes. SEARCH METHODS: We searched the Cochrane Tobacco Addiction Specialized Register, which includes reports of trials indexed in the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, and PsycINFO, clinicaltrials.gov, the ICTRP, and other reviews and meeting abstracts, in May 2019. SELECTION CRITERIA: We included randomized controlled trials (RCTs) that recruited smokers, and compared antidepressant medications with placebo or no treatment, an alternative pharmacotherapy, or the same medication used in a different way. We excluded trials with less than six months follow-up from efficacy analyses. We included trials with any follow-up length in safety analyses. DATA COLLECTION AND ANALYSIS: We extracted data and assessed risk of bias using standard Cochrane methods. We also used GRADE to assess the certainty of the evidence. The primary outcome measure was smoking cessation after at least six months follow-up, expressed as a risk ratio (RR) and 95% confidence intervals (CIs). We used the most rigorous definition of abstinence available in each trial, and biochemically validated rates if available. Where appropriate, we performed meta-analysis using a fixed-effect model. Similarly, we presented incidence of safety and tolerance outcomes, including adverse events (AEs), serious adverse events (SAEs), psychiatric AEs, seizures, overdoses, suicide attempts, death by suicide, all-cause mortality, and trial dropout due to drug, as RRs (95% CIs). MAIN RESULTS: = 0%; 3 studies, 417 participants). There was no evidence that any of the other antidepressants tested (including St John's Wort, selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAOIs)) had a beneficial effect on smoking cessation. Findings were sparse and inconsistent as to whether antidepressants, primarily bupropion and nortriptyline, had a particular benefit for people with current or previous depression. AUTHORS' CONCLUSIONS: There is high-certainty evidence that bupropion can aid long-term smoking cessation. However, bupropion also increases the number of adverse events, including psychiatric AEs, and there is high-certainty evidence that people taking bupropion are more likely to discontinue treatment compared with placebo. However, there is no clear evidence to suggest whether people taking bupropion experience more or fewer SAEs than those taking placebo (moderate certainty). Nortriptyline also appears to have a beneficial effect on smoking quit rates relative to placebo. Evidence suggests that bupropion may be as successful as NRT and nortriptyline in helping people to quit smoking, but that it is less effective than varenicline. There is insufficient evidence to determine whether the other antidepressants tested, such as SSRIs, aid smoking cessation, and when looking at safety and tolerance outcomes, in most cases, paucity of data made it difficult to draw conclusions. Due to the high-certainty evidence, further studies investigating the efficacy of bupropion versus placebo are unlikely to change our interpretation of the effect, providing no clear justification for pursuing bupropion for smoking cessation over front-line smoking cessation aids already available. However, it is important that where studies of antidepressants for smoking cessation are carried out they measure and report safety and tolerability clearly.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd000031.pub5

Cites

375 of 375 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 16

  1. Brauer LH, Paxton DA, Stock CT, Rose JE. Selegiline and transdermal nicotine for smoking cessation. Society for Research on Nicotine and Tobacco Annual Conference; 2000 Feb 18-20; Arlington (VA) 2000.
  2. Croghan IT, Hurt RD, Croghan GA, Sloan JA. Comparing nicotine inhaler, bupropion and nicotine inhaler plus bupropion in treating tobacco dependence [abstract]. Nicotine & Tobacco Research 2005;7:680-1. [Google Scholar]
  3. Evins AE, Alpert JE, Pava J, Petersen TJ, Farabaugh AH, Fava M. A double blind placebo controlled trial of bupropion added to nicotine patch and cognitive behavioral therapy in smokers with current or past unipolar depressive disorder. Neuropsychopharmacology 2005;30 Suppl 1:S91. [Google Scholar]
  4. Frederick SL, Hall SM, Sees KL. The effect of venlafaxine on smoking cessation in subjects with and without a history of depression. NIDA Research Monograph 1997;174:208. [Google Scholar]
  5. Grandi S, Shimony A, Eisenberg MJ. The efficacy and safety of bupropion started in-hospital for smoking cessation in patients with cardiovascular disease: A systematic review and meta-analysis. Circulation 2011;124(21 Suppl 1). 9400123000012459 [9400123000012459]
  6. Hitsman B, Spring B, Borrelli B, Niaura R, Papandonatos G. Adherence to medication versus behavioral therapy as predictors of smoking cessation in combined treatment involving fluoxetine [abstract]. Society for Research on Nicotine and Tobacco Annual Conference; 2000 Feb 18-20; Arlington (VA) 2000.
  7. Li J, Zhang T, Wang B, Li X. An efficacy analysis of bupropion for smoking cessation in schizophrenia. Zhongguo Xinyao Yu Linchuang Zazhi [Chinese Journal of New Drugs and Clinical Remedies] 2009;28(3):231-4. 9400123000016534
  8. NCT00670904. Randomized trial assessing the effectiveness of a pharmacist-delivered program for smoking cessation. clinicaltrials.gov/show/NCT00670904 (first received 2 May 2008). [DOI] [PubMed]
  9. Gratziou C, Rovina N, Athanassa Z, Francis K, Evangelou E, Chiotis D, et al. Evaluation of prolonged bupropion treatment as an aid in smoking cessation [abstract]. European Respiratory Journal 2002;20 Suppl 38:611s. [Google Scholar]
  10. Rovina N, Gratziou C, Nikoloutsou I, Athanassa Z, Francis K, Roussos C. Short or prolonged treatment with bupropion HCL in smoking cessation therapy. European Respiratory Journal 2003;22 Suppl 45:165s. [Google Scholar]
  11. Sittipunt C, Kawkitinarong K, Wongtim S, Udompanich V. The effectiveness of nortriptyline plus brief motivation counseling for the treatment of smoking cessation in Thai active smokers [Abstract]. Respirology 2007;12(Suppl 4):A223. [Google Scholar]
  12. Sonntag H, Hoch E, Jahn B, Spiegel B, Pfister H, Wittchen HU. Smoking cessation in primary care: implementation effectiveness and optimized allocation. Suchtmedizin in Forschung und Praxis 2003;5:137-41. [Google Scholar]
  13. Centers for Disease Control and Prevention. Quitting Smoking Among Adults—United States, 2000–2015. Morbidity and Mortality Weekly Report 2017;52:1457-64. [DOI] [PubMed] [Google Scholar]
  14. Fiore MC, Jaén CR, Baker TB, et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. AHRQ publication No. 00-0032. Rockville, MD: US Dept of Health and Human Services. Public Health Services, 2008. [Google Scholar]
  15. Hughes JR. Non-nicotine pharmacotherapies for smoking cessation. Journal of Drug Development 1994;6:197-203. [Google Scholar]
  16. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database of Systematic Reviews 2002, Issue 1. [DOI] [PubMed] [Google Scholar]

Cited by

Sorted by citations

Related

Authors
Howes, S., Hartmann-Boyce, J., Livingstone-Banks, J., Hong, B., & Lindson, N.
Affiliations
  • University of Oxford (GB)
  • Nuffield Department of Primary Care Health Sciences; University of Oxford; Oxford UK
  • Birmingham Dental Hospital (GB)
ORCID
Lindson, Nicola
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2020-04-22
Volume
2021
Issue
5
Pages
CD000031-CD000031
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
DOI
10.1002/14651858.cd000031.pub5
PMC
PMC7175455
OpenAlex
W1549559727
Cited by
1,352
References
372
Citations by year
2026: 2 · 2025: 11 · 2024: 26 · 2023: 55 · 2022: 49 · 2021: 45 · 2020: 81 · 2019: 28 · 2018: 32 · 2017: 42 · 2016: 55 · 2015: 75 · 2014: 51 · 2013: 83 · 2012: 91
FWCI
7.32
Type
journal article
Language
en
Update notices
new_version (2023-05-24)
Open access
Locations
  • Cochrane Database of Systematic Reviews (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Physiology › Smoking Behavior and Cessation
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
Keywords
antidepressants, smoking cessation, nicotine withdrawal, nicotine dependence, bupropion, nortriptyline, selective serotonin reuptake inhibitors, monoamine oxidase inhibitors, Hypericum perforatum, depression, adverse events, drug safety and tolerability, long-term abstinence, nicotine replacement therapy, smoking cessation pharmacotherapy, nicotine withdrawal symptoms
MeSH terms
Varenicline, Antidepressive Agents, Humans, Nortriptyline, Smoking, Anti-Anxiety Agents, Randomized Controlled Trials as Topic, Smoking Cessation, Bupropion, Selective Serotonin Reuptake Inhibitors, Tobacco Use Cessation Devices

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review